Abstract
Microfluidically (MF) synthesized lipid nanoparticles (LNPs) for antisense oligonucleotides (ODN) delivery have been shown to be superior to those prepared by bulk mixing (BM). In this study, a 5-inlet MF chip was used to synthesize LNPs loaded with LOR-2501, an antisense ODN targeting the ribonucleotide reductase R1 subunit. The size distribution of ODN- LNPs was measured by dynamic light scattering. The cytotoxicity of ODN- LNPs was determined by MTS assay. Gene silencing activity of ODN- LNPs was investigated by qRT-PCR and by Western blot. Results showed that MF synthesis produced ODN-LNPs that have lower average size and polydispersity values. The highest antisense activity was shown by LNs synthesized by the MF T2 chip, with downregulation of R1 mRNA by 32.5%. In conclusion, given their simplicity, affordability and reproducibility, MF is an attractive method for synthesis of LNs for ODN delivery.
Keywords: Antisense oligonucleotide, cancer, microfluidics, nanoparticles, ribonucleotide reductase.
Current Pharmaceutical Biotechnology
Title:Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides
Volume: 15 Issue: 9
Author(s): Yulin Zhou, Zhaoli Meng, Tianqi Guo, Yige Fu, Robert J. Lee and Jing Xie
Affiliation:
Keywords: Antisense oligonucleotide, cancer, microfluidics, nanoparticles, ribonucleotide reductase.
Abstract: Microfluidically (MF) synthesized lipid nanoparticles (LNPs) for antisense oligonucleotides (ODN) delivery have been shown to be superior to those prepared by bulk mixing (BM). In this study, a 5-inlet MF chip was used to synthesize LNPs loaded with LOR-2501, an antisense ODN targeting the ribonucleotide reductase R1 subunit. The size distribution of ODN- LNPs was measured by dynamic light scattering. The cytotoxicity of ODN- LNPs was determined by MTS assay. Gene silencing activity of ODN- LNPs was investigated by qRT-PCR and by Western blot. Results showed that MF synthesis produced ODN-LNPs that have lower average size and polydispersity values. The highest antisense activity was shown by LNs synthesized by the MF T2 chip, with downregulation of R1 mRNA by 32.5%. In conclusion, given their simplicity, affordability and reproducibility, MF is an attractive method for synthesis of LNs for ODN delivery.
Export Options
About this article
Cite this article as:
Zhou Yulin, Meng Zhaoli, Guo Tianqi, Fu Yige, Lee J. Robert and Xie Jing, Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/1389201015666141020155417
DOI https://dx.doi.org/10.2174/1389201015666141020155417 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Cryptococcocal Infection
Current Respiratory Medicine Reviews Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Subject Index To Volume 6
Anti-Cancer Agents in Medicinal Chemistry Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy
Recent Patents on Biotechnology Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery